Santa Lucia Foundation Istituto di Ricovero e Cura a Carattere Scientifico, 00143 Rome, Italy.
J Neurosci. 2010 Apr 14;30(15):5176-88. doi: 10.1523/JNEUROSCI.5351-09.2010.
Amyotrophic lateral sclerosis-Parkinson dementia complex (ALS-PDC) is a neurodegenerative disease with ALS, parkinsonism, and Alzheimer's symptoms that is prevalent in the Guam population. beta-N-Methylamino alanine (BMAA) has been proposed as the toxic agent damaging several neuronal types in ALS-PDC, including substantia nigra pars compacta dopaminergic (SNpc DAergic) neurons. BMAA is a mixed glutamate receptor agonist, but the specific pathways activated in DAergic neurons are not yet known. We combined electrophysiology, microfluorometry, and confocal microscopy analysis to monitor membrane potential/current, cytosolic calcium concentration (Ca(2+)) changes, cytochrome-c (cyt-c) immunoreactivity, and reactive oxygen species (ROS) production induced by BMAA. Rapid toxin applications caused reversible membrane depolarization/inward current and increase of firing rate and Ca(2+) in DAergic neurons. The inward current (I(BMAA)) was mainly mediated by activation of metabotropic glutamate receptor 1 (mGluR1), coupled to transient receptor potential (TRP) channels, and to a lesser extent, AMPA receptors. Indeed, mGluR1 (CPCCOEt) and TRP channels (SKF 96365; Ruthenium Red) antagonists reduced I(BMAA), and a small component of I(BMAA) was reduced by the AMPA receptor antagonist CNQX. Calcium accumulation was mediated by mGluR1 but not by AMPA receptors. Application of a low concentration of NMDA potentiated the BMAA-mediated calcium increase. Prolonged exposure to BMAA caused significant modifications of membrane properties, calcium overload, cell shrinkage, massive cyt-c release into the cytosol and ROS production. In SNpc GABAergic neurons, BMAA activated only AMPA receptors. Our study identifies the mGluR1-activated mechanism induced by BMAA that may cause the neuronal degeneration and parkinsonian symptoms seen in ALS-PDC. Moreover, environmental exposure to BMAA might possibly also contribute to idiopathic PD.
肌萎缩性侧索硬化症-帕金森痴呆复合征(ALS-PDC)是一种神经退行性疾病,在关岛人群中较为常见,其特征为 ALS、帕金森病和阿尔茨海默病症状。β-N-甲基氨基丙氨酸(BMAA)被认为是一种有毒物质,可损伤 ALS-PDC 中的几种神经元类型,包括黑质致密部多巴胺能(SNpc DAergic)神经元。BMAA 是一种混合型谷氨酸受体激动剂,但 DAergic 神经元中激活的特定途径尚不清楚。我们结合电生理学、微荧光计和共聚焦显微镜分析来监测膜电位/电流、细胞溶质钙离子浓度(Ca(2+))变化、细胞色素 c(cyt-c)免疫反应性和由 BMAA 诱导的活性氧物质(ROS)产生。快速毒素应用引起 DAergic 神经元的可逆膜去极化/内向电流和放电率和Ca(2+)增加。内向电流(I(BMAA))主要通过代谢型谷氨酸受体 1(mGluR1)的激活介导,与瞬时受体电位(TRP)通道偶联,在较小程度上,与 AMPA 受体偶联。事实上,mGluR1(CPCCOEt)和 TRP 通道(SKF 96365;钌红)拮抗剂减少 I(BMAA),并且 AMPA 受体拮抗剂 CNQX 减少 I(BMAA)的一小部分。钙积累由 mGluR1 介导,但不由 AMPA 受体介导。低浓度 NMDA 的应用增强了 BMAA 介导的钙增加。长时间暴露于 BMAA 导致膜性质的显著改变、钙超载、细胞收缩、大量 cyt-c 释放到细胞质和 ROS 产生。在 SNpc GABAergic 神经元中,BMAA 仅激活 AMPA 受体。我们的研究确定了由 BMAA 诱导的 mGluR1 激活机制,该机制可能导致 ALS-PDC 中观察到的神经元变性和帕金森症状。此外,环境暴露于 BMAA 也可能导致特发性 PD。